| Name | Title | Contact Details |
|---|
Greater Iowa Credit Union (GICU) is a member-owned financial cooperative established in June 1932 by a group of Iowa State University employees. It has grown to serve over 36,000 members across a 33-county area in Central and Western Iowa, managing assets between $624 million and $667 million. GICU is federally insured and state-chartered, emphasizing its commitment to the financial well-being of its members and the communities it serves. GICU offers a range of financial services typical of credit unions, including banking services like checking and savings accounts, loans for personal, auto, and business needs, and possibly investment services. The credit union operates nine branch locations in cities such as Ames, Ankeny, and Des Moines, providing localized service. GICU is also dedicated to community engagement, having received recognition as the Best Credit Union in Crawford County and Story County multiple times.
Providing real-time asset tracking in any environment, with applications in manufacturing, defense, energy, inventory management, logistics, and security. WISERs ultra-wideband (UWB) system operates without line-of-sight and registers asset locations within inches in most cases.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
GEICO is a Maryland-based financial institution that provides personal and commercial insurance products for individuals and businesses.
The Essmueller Company is an Equipment Manufacturer located in Laurel, Mississippi, United States. We build Bulk Material Handling Equipment for the Grain and Processing industries